The FTC has paused its antitrust case against major PBMs, citing a lack of commissioners. The lawsuit alleges unfair practices that inflated insulin prices.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers industry, including CVS Health (NYSE:CVS) and its peers.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers industry, including Cencora (NYSE:COR) and its peers.
Let’s dig into the relative performance of Clover Health (NASDAQ:CLOV) and its peers as we unravel the now-completed Q4 health insurance providers earnings season.
A lawsuit has been lodged against JPMorgan Chase by its employees, who claim that the company's prescription drug plan consented to pay exorbitant prices for medications.
CVS Weight Management program members achieved 15% average weight loss, with 92% satisfaction and 26% lower GLP-1 medication costs for participating clients.
The CPI and PPI releases this week came in more or less at estimates - nothing to alarm the talking heads, anyway. They show inflation slowing down but not receding.
As the United States stock market continues to drop, investors are turning their attention to defensive investments. Dividend stocks have always been an investor favorite when prices start to drop, providing immediate income that can potentially offset falling prices in other areas.
Walgreens Boots Alliance agreed to an $11.45 per share buyout by Sycamore Partners, but shareholders can reject the deal and holdout for a better offer.
CVS Health has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.4%. The stock now trades at $65.60, marking a 15.2% gain. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among Stocktwits users for the week ended March 7, 2025.
